Onat Kadioglu
Overview
Explore the profile of Onat Kadioglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asensio M, Briz O, Herraez E, Perez-Silva L, Espinosa-Escudero R, Bueno-Sacristan D, et al.
Biomed Pharmacother
. 2024 Oct;
180:117533.
PMID: 39405909
Aims: Drug export through ABC proteins hinders cancer response to chemotherapy. Here, we have evaluated the relevance of MRP3 (ABCC3) in cholangiocarcinoma (CCA) as a potential target to overcome drug...
2.
Schafer J, Klosgen V, Omer E, Kadioglu O, Mbaveng A, Kuete V, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373385
Cancer therapy with clinically established anticancer drugs is frequently hampered by the development of drug resistance of tumors and severe side effects in normal organs and tissues. The demand for...
3.
Qu Y, Song L, Xu S, Yu M, Kadioglu O, Michelangeli F, et al.
Pharmacol Res
. 2023 Apr;
191:106769.
PMID: 37061145
Drug resistance in cancer has been classified as innate resistance or acquired resistance, which were characterized by apoptotic defects and ABC transporters overexpression respectively. Therefore, to preclude or reverse these...
4.
Kadioglu O, Bahramimehr F, Dawood M, Mahmoud N, Elbadawi M, Lu X, et al.
Comput Biol Med
. 2023 Mar;
157:106781.
PMID: 36931205
RNA-sequencing has been proposed as a valuable technique to develop individualized therapy concepts for cancer patients based on their tumor-specific mutational profiles. Here, we aimed to identify drugs and inhibitors...
5.
Saeed M, Yucer R, Dawood M, Hegazy M, Drif A, Ooko E, et al.
Int J Mol Sci
. 2022 Apr;
23(7).
PMID: 35409325
The improvement of cancer chemotherapy remains a major challenge, and thus new drugs are urgently required to develop new treatment regimes. Curcumin, a polyphenolic antioxidant derived from the rhizome of...
6.
Ozenver N, Kadioglu O, Fu Y, Efferth T
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163434
Pigeon Pea ( (L.) Millsp.) is a common food crop used in many parts of the world for nutritional purposes. One of its chemical constituents is cajanin stilbene acid (CSA),...
7.
Kadioglu O, Elbadawi M, Fleischer E, Efferth T
Pharmaceuticals (Basel)
. 2021 Oct;
14(10).
PMID: 34681275
Differentially expressed genes have been previously identified by us in multidrug-resistant tumor cells mainly resistant to doxorubicin. In the present study, we exemplarily focused on some of these genes to...
8.
Wu X, Yin C, Ma J, Chai S, Zhang C, Yao S, et al.
Acta Pharm Sin B
. 2021 Aug;
11(7):1885-1902.
PMID: 34386326
Multidrug resistance (MDR) mediated by ATP binding cassette subfamily B member 1 (ABCB1) is significantly hindering effective cancer chemotherapy. However, currently, no ABCB1-inhibitory drugs have been approved to treat MDR...
9.
Coghi P, Ng J, Kadioglu O, Law B, Qiu A, Saeed M, et al.
Eur J Med Chem
. 2021 Jul;
224:113676.
PMID: 34256125
A series of eleven celastrol derivatives was designed, synthesized, and evaluated for their in vitro cytotoxic activities against six human cancer cell lines (A549, HepG2, HepAD38, PC3, DLD-1 Bax-Bak WT...
10.
Kadioglu O, Klauck S, Fleischer E, Shan L, Efferth T
Arch Toxicol
. 2021 May;
95(7):2485-2495.
PMID: 34021777
The majority of drug candidates fails the approval phase due to unwanted toxicities and side effects. Establishment of an effective toxicity prediction platform is of utmost importance, to increase the...